Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Additional Metadata
Keywords	Early response, Immune thrombocytopenia, Open label phase II, Rituximab, Splenectomy delaying
Persistent URL	doi.org/10.3324/haematol.2014.110213, hdl.handle.net/1765/89667
Journal	Haematologica
Note	on behalf of the Dutch HOVON 64 study group
Organisation	Erasmus MC Cancer Institute
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Zwaginga, J., van der Holt, B., te Boekhorst, P., Biemond, B., Levin, M.-D., van der Griend, R., Brand, A., Zweegman, S., Pruijt, H., Novotny, V., Vreugdenhil, A., de Groot, M., de Weerdt, O., van Pampus, E., van Maanen-Lamme, T., Wittebol, S., Schipperus, M., Silbermann, M., Huijgens, P., … Koene, H. (2015). Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica, 100(3), e90–e92.https://doi.org/10.3324/haematol.2014.110213

Publication